Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
about
Tyrosine kinase inhibitors for unresectable hepatocellular carcinoma in adultsRole of sorafenib in the treatment of advanced hepatocellular carcinoma: An updateTreatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive reviewSorafenib: from literature to clinical practiceEmerging trends in hepatocellular carcinoma: focus on diagnosis and therapeuticsFirst- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response EvaluationReal-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON DataAdoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review.Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON RegistryCost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials.The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinomaImmune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.Impact of restricting access to high-cost medications for hepatocellular carcinoma.Refining sorafenib therapy: lessons from clinical practice.Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update.First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus.Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
P2860
Q24187730-613DD3D8-D61D-4591-8AFA-44540051ABEFQ24619987-7410436B-20FD-4DFD-8E32-0B53D6F5F507Q26772299-07368D2C-6BB4-414A-9A3D-BB12E082427DQ26826933-3D6D5ED4-D08A-45D2-A1DE-D506CD16EC35Q26851272-D3F8C401-AE1E-447D-83BB-8F096FBDB687Q28073654-13132628-34BB-4E20-90C9-C7C47B133BA0Q31048824-6416F017-A613-4FCA-9458-725E91F991D9Q34101953-0FCEE562-560B-4680-917D-3DB6F770875CQ34552160-295FFD6A-F157-41A6-951E-36A87584A840Q34693220-10E9D259-62CB-41EB-82D4-7FD2839BBFE2Q36325065-426A8BC0-CE1F-4F3D-BCBB-C6D110B63D52Q36682439-1A29F6AA-E7CA-48B3-AC54-B45095D056ECQ36911277-AEA96792-9760-4325-B109-E72EFF630CF9Q36916295-BEBEF223-E4D8-483A-AF41-A30528842D83Q37017008-291A38EE-8483-48AC-8A23-049317977B79Q37253389-05516BF3-EE6F-4F4E-9F07-718269BC5301Q37393627-FEF0B0FC-B249-4194-9373-17C73D08AA84Q37433645-F875E531-677E-430D-98F9-8E276ECF862BQ37827878-7EE6F00A-05EB-4FC0-9A4C-851A6824954AQ37952231-70D74A1B-400A-4E3A-9BDD-94B591597AB4Q38042711-53ED18BF-F51D-4B8F-B9B7-795F49C2E9B7Q38264146-3A1FD32C-08C6-4336-88E2-343DB7E04FF9Q38986591-99BC2095-8F77-4235-8221-5CDD97E392FEQ39979280-7DCC79EF-C55E-45BB-B603-8E5FE6DA23C6Q43804593-E73D793A-3013-4468-A293-34161875ECBBQ44079528-CB62AF7D-1D0C-473B-BB69-37BF8700DD9BQ44599939-696BA6E8-4E9C-4D9C-807D-172B643F8A55Q45299134-5A083024-1334-442D-9FD2-A31B48060528Q48250035-ABB78BD8-E2FA-4988-BFF1-1217DC0C1852Q48722303-55D5CAE1-66E4-4401-B621-516FFE4990C9Q52663015-00740BD9-B8DB-4D11-A289-8B7269AF0598Q52676764-D6ED3CB3-64FE-4412-8968-4F975715EA40
P2860
Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Design and rationale for the n ...... with Sorafenib (GIDEON) study.
@ast
Design and rationale for the n ...... with Sorafenib (GIDEON) study.
@en
Design and rationale for the n ...... f its Treatment with Sorafenib
@nl
type
label
Design and rationale for the n ...... with Sorafenib (GIDEON) study.
@ast
Design and rationale for the n ...... with Sorafenib (GIDEON) study.
@en
Design and rationale for the n ...... f its Treatment with Sorafenib
@nl
prefLabel
Design and rationale for the n ...... with Sorafenib (GIDEON) study.
@ast
Design and rationale for the n ...... with Sorafenib (GIDEON) study.
@en
Design and rationale for the n ...... f its Treatment with Sorafenib
@nl
P2093
P2860
P1476
Design and rationale for the n ...... with Sorafenib (GIDEON) study.
@en
P2093
P2860
P304
P356
10.1111/J.1742-1241.2010.02414.X
P577
2010-07-01T00:00:00Z